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OBJECTIVE—SIRT1 has pleiotropic metabolic functions. We
investigated whether SIRT1 genetic variation is associated with
obesity.
RESEARCH DESIGN AND METHODS—In 6,251 elderly sub-
jects from the prospective, population-based Rotterdam Study,
three single nucleotide polymorphisms (SNPs) in the SIRT1 gene
were studied in relation to BMI and risk of obesity (BMI 30
kg/m
2) and prospectively with BMI change after 6.4 years of
follow-up. We used cross-sectional data from 2,347 participants
from the Erasmus Rucphen Family (ERF) study for replication.
RESULTS—Minor alleles of rs7895833 (G  20.2%) and
rs1467568 (A  36.8%) were associated with lower BMI in the
Rotterdam Study (P  0.02 and 0.04) and in the replication
cohort ERF study (P  0.03 and 0.008) and in both studies
combined (P  0.002 for both SNPs), with a 0.2–0.4 kg/m
2
decrease in BMI per allele copy. Carriers of these alleles had
13–18% decreased risk of obesity (for rs7895833 in the Rotterdam
Study: odds ratio 0.79 [95% CI 0.67–0.94], P  0.007; in the ERF
study: 0.93 [0.73–1.19], P  0.37; and in the studies combined 0.87
[0.77–0.97], P  0.02; for rs1467568 in the Rotterdam Study: 0.80
[0.68–0.94], P  0.007; in the ERF study: 0.85 [0.72–0.99], P 
0.04; and in the studies combined: 0.82 [0.73–0.92], P  0.0009).
In the Rotterdam Study, the two variants were also associated
with a lower BMI increase during 6.4 years of follow-up (P  0.01
and 0.08).
CONCLUSIONS—Two common variants in SIRT1 are associ-
ated with lower BMI in two independent Dutch populations.
Carriers of these variants have 13–18% decreased risk of obesity
and gain less weight over time. The availability of SIRT1 stimu-
lators makes these ﬁndings relevant in light of the growing
obesity epidemic. Diabetes 58:2828–2834, 2009
S
IRT1 belongs to the Sirtuin protein family of
nicotinamide adenine dinucleotide (NAD
)-de-
pendent histone deacetyleases conserved in evo-
lution from bacteria to humans. In lower
organisms such as yeast, ﬂies, and worms, the silent
information regulator Sir2 protein is related to longevity
(1,2) and to lifespan extension after caloric restriction
(3–5). Humans have seven sirtuins (SIRT1–7) (6), of which
SIRT1 has the highest homology to yeast Sir2. SIRT1
controls numerous physiological processes and protects
cells against stress (2,7–13). SIRT1 also has an important
function in endocrine signaling, speciﬁcally in glucose and
fat metabolism (14–18). Increased hepatic SIRT1 activity
enhances gluconeogenesis and inhibits glycolysis (15,16).
In the pancreas, SIRT1 stimulates insulin secretion in
response to glucose (17,18). In adipose tissue, SIRT1
interacts with peroxisome proliferator–activated receptor
(PPAR)- to repress its transcriptional activity, leading to
inhibition of adipogenesis during fasting and activation of
lipolysis (14). This results in fat loss, which is an important
component of the effect of caloric restriction on longevity
in mammals (14). It is not known whether caloric restric-
tion can extend lifespan in humans, but clear beneﬁcial
effects on cardiovascular risk factors have been described
(19,20). Fasting leads to upregulation of SIRT1 in adipose
tissue of mice, pigs, and humans (21–23). Based on ﬁnd-
ings in lower organisms, it has been hypothesized that
stimulation of SIRT1 by agonists may mimic the beneﬁcial
effects of caloric restriction in mammals. Resveratrol, a
naturally occurring SIRT1 agonist present in red wine and
grapes, was indeed recently shown to prevent diet-induced
obesity and insulin resistance in mice and to improve their
survival on a high-calorie diet (24,25). If activation of
SIRT1 can result in loss of body fat without decreasing
caloric intake, this could open the door for novel treat-
ment and prevention strategies for obesity and related
diseases. However, in humans, effects of SIRT1 stimu-
lation have not been investigated in vivo, and there is
concern that generalized SIRT1 activation may also
have pro-ageing or adverse health effects, due to poten-
tial pleiotropic and tissue-dependent physiological func-
tions (26–29).
Based on the above ﬁndings, we hypothesized that
genetic variation in SIRT1 may inﬂuence BMI and the risk
of obesity in humans. Previous smaller studies, which have
examined the relation between variants in SIRT1 and
obesity, have led to inconsistent ﬁndings. A recent case-
control study of 1,068 obese patients and 313 normal-
weight control subjects found a SIRT1 single nucleotide
polymorphism (SNP) associated with obesity risk. Unex-
pectedly, male but not female carriers of the allele asso-
ciated with lower obesity risk had increased visceral
adiposity on computed tomography scans. This was ob-
served only after adjustment for BMI (30). Another recent
small study (31) investigating associations of SIRT1 SNPs
with metabolic response to lifestyle intervention found no
association of four SIRT1 SNPs in 917 overweight subjects
with baseline BMI or with BMI change after 9 months
follow-up. No population-based studies with large sample
size and replication are available on the association be-
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and risk of obesity. We therefore assessed the association
of variation in the SIRT1 gene with BMI and the risk of
being overweight or obese in the large cohort of elderly
subjects of the Rotterdam Study. For replication, we used
subjects with a wide age range from a genetically isolated
population in the Netherlands, participating in the Eras-
mus Rucphen Family (ERF) study. In the Rotterdam
Study, we also assessed prospectively the relation of
SIRT1 variants with BMI change on follow-up.
RESEARCH DESIGN AND METHODS
The Rotterdam Study. The Rotterdam Study is a prospective, population-
based cohort study among 7,983 subjects aged 55 years from the district of
Rotterdam, the Netherlands. The study was designed to investigate the
incidence and determinants of chronic disabling diseases. Rationale and
design have been described previously (32,33). Informed consent was ob-
tained from each participant, and the medical ethics committee of the
Erasmus Medical Center Rotterdam approved the study. At baseline (1990–
1993), all participants were interviewed and underwent extensive physical
examination. At the second follow-up (1997–1999), these examinations were
performed according to the same protocol.
The ERF study. This study is a family-based cohort study that is embedded
in the Genetic Research in Isolated Populations Program in the southwest of
the Netherlands. The aim of this program was to identify genetic risk factors
in the development of complex disorders (34–36). For the ERF study, 22
families that had at least ﬁve children baptized in the community church
between 1850 and 1900 were identiﬁed with the help of genealogical records.
All living descendants of these couples and their spouses were invited to take
part in the study. Data collection started in June 2002 and was ﬁnished in
February 2005. In this study, we focused on 2,347 participants for whom
complete phenotypic, genotypic, and genealogical information was available.
The medical ethics committee of Erasmus Medical Center Rotterdam ap-
proved of both studies, and informed consent was obtained from all partici-
pants.
Measurements. For the two studies, identical protocols were used for
assembling phenotypic and genotypic information. Height (cm) and weight
(kg) were measured at the initial examination and, in the Rotterdam Study,
also at follow-up examinations, in standing position wearing indoor clothes
without shoes. BMI was computed as weight in kilograms divided by height in
meters squared (kg/m
2).
Genotyping. Three tagging SNPs, rs7895833, rs1467568, and rs497849, were
selected from the HapMap database (available at http://www.hapmap.org)
that, together with constructed haplotypes, covered 100% of the common
(minor allele frequency 10%) variation of the SIRT1 gene in Caucasians.
Genotyping of the SIRT1 SNPs was performed by Taqman on genomic DNA
isolated from peripheral leukocytes by standard salting-out procedures.
Results were analyzed by the ABI Taqman 7900HT using the sequence
detection system 2.22 software (Applied Biosystems, Foster City, CA). To
conﬁrm the accuracy of genotyping results, 332 (5%) randomly selected
samples were regenotyped with the same method. No inconsistencies were
observed. All used primers and probes are available on request.
Statistical analyses. Hardy-Weinberg equilibrium of the three SIRT1 SNPs
was tested with the GENEPOP package (37). Subjects were grouped accord-
ing to genotype for individual SNP alleles and by allele copy number of
haplotype alleles. We inferred multimarker haplotypes in the Rotterdam Study
only from these SNPs using the program Phase (38). In the ERF study,
haplotypes were not determined because they could not be inferred with high
certainty due to the complex pedigree structure.
Haplotype alleles were numbered in order of decreasing frequency in the
population (Fig. 1). Subjects were grouped according to genotype. Genotype
groups were based on allele copy number (0, 1, and 2, corresponding to
noncarriers, heterozygote carriers, and homozygote carriers, respectively, of
the most common haplotype alleles).
The relation between BMI and SIRT1 genotypes was assessed using linear
regression analysis, assuming an additive model. The odds ratio of being
overweight (BMI 25 kg/m
2) or obese (BMI 30 kg/m
2) compared with
normal weight (BMI 18.5–25 kg/m
2) was assessed using logistic regression.
The 95% CIs of the odds ratios (ORs) were calculated as the exponent of the
regression coefﬁcient and its standard error. For the assessment of an
association between SIRT1 genotypes and BMI at follow-up in the Rotterdam
Study, we used BMI data of the second follow-up measurement, which was
(means  SD) 6.4  0.4 years after baseline. Linear regression analysis was
also used for the association between SIRT1 genotypes and BMI change from
baseline to second follow-up.
In the Rotterdam Study, genetic outliers as identiﬁed by the identity-by-
state (IBS) clustering analysis clustering 3 SDs away from the population
mean were removed prior to the analyses. Therefore, this population is
ethnically homogenous. P values were corrected by the inﬂation factor using
genomic control method (39). In the Rotterdam Study, s (obtained after
running genome-wide association [GWA] analysis for these traits) were small
(1.049, 1.045, and 1.036 for BMI, the risk of overweight, and the risk of obesity,
respectively).
Since genetic association may be inﬂuenced by family relationships, we
performed the analyses in the ERF study with a polygenic model using a
variance component approach with the pedigree information in SOLAR
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FIG. 1. Schematic representation of the SIRT1 gene with the localization of the three tagging SNPs. A: LD plot of the SNPs with estimates of r
2
in the upper right corner and D in the left lower corner. B: Haplotype construction and observed frequencies of the haplotypes in the Rotterdam
Study.
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sfbrgenetics.org]). The program takes into account the familial relationships
by estimating heritability from the pedigree data. Subsequently, analyses were
corrected for residual genomic inﬂation, which was very small (1.02,
values obtained from GWA studies).
We performed a meta-analysis using ﬁxed effects on the results of the two
cohorts using the software Review Manager (available at www.cc-ims.net/
RevMan/RevMan5). We performed a search to add data from the literature to
our meta-analysis using PubMed, with the search terms in humans “SIRT1” or
“SIRT1 and polymorphisms” and “overweight” or “obesity” or “BMI” or “body
weight” on 1 April 2009. Only two studies (30,31) were found. Because the
study by Weirich et al. (31) was small and contained no information on the risk
of obesity, we performed meta-analysis for the risk of obesity using results
from the Rotterdam and ERF studies, together with the published data from
the study by Peeters et al. (30). We used the rs1467568 and rs7069102 SNPs,
which are in almost perfect linkage disequilibrium (LD) (D0.99 and r
2 
0.96) to meta-analyze results across studies. All analyses were adjusted for age
and sex. The statistical analyses were performed using SPSS software (version
15.0) in the Rotterdam Study and with SOLAR software (package 2.1.2) in the
ERF study.
RESULTS
General characteristics. In Table 1, baseline character-
istics of the two study populations are presented. In both
studies, a slight majority of participants were females. BMI
was 1.1% higher in subjects from the ERF study than in the
Rotterdam Study at baseline.
SIRT1 genotype. Figure 1 shows the schematic represen-
tation of the SIRT1 locus with the localization of the three
tagging SNPs and an LD plot of the SNPs (D and r
2)a s
well as haplotype construction and observed frequencies
of the haplotypes in the Rotterdam Study. In the Rotter-
dam Study, allele and genotype distributions of the three
tagging SNPs of SIRT1 follow Hardy-Weinberg equilibrium
proportions (P  0.10). LD between the SNPs was high (D
 0.8), which enabled us to infer multimarker haplotypes
in the Rotterdam Study with high conﬁdence. The haplo-
type frequencies of the four most common haplotypes
were 40.9, 22.1, 20.0, and 16.7%. As shown in Fig. 1,
rs497849 fully tags haplotype 2 and rs7895833 fully tags
haplotype 3. In the ERF study, we genotyped the two SNPs
showing association with obesity in the Rotterdam Study.
These SNPs showed slightly different frequencies between
the two studies but were also in Hardy-Weinberg equilib-
rium proportions in the ERF study.
Relation of SIRT1 variants with BMI. Table 2 shows
the relationship of SIRT1 SNPs with BMI in the Rotterdam
Study at baseline and at the second follow-up examination
and the replication data of two SIRT1 SNPs in the ERF
TABLE 1
General and body composition characteristics of two study
populations
Rotterdam Study ERF study
n 6,251 2,347
Women 3,665 (59) 1,385 (55)
Age (years) 69.1  8.8 47.5  13.8
Range 55.1–99.0 17.6–85.3
Height (m) 1.67  0.09 1.68  0.09
Weight (kg) 73.2  12.0 75.3  15.4
BMI (kg/m
2) baseline 26.3  3.7 26.6  4.4
BMI (kg/m
2) at follow-up 2
(n  3,630) 26.8  3.9
BMI change (kg/m
2)* 0.55  1.8
Range 10.0 to 11.0
Data are means  SD or n (%), unless otherwise indicated. *Change
in BMI from baseline to follow-up 2 examination.
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rs7895833 and rs1467568, had a signiﬁcant association
with BMI at baseline (P  0.02 and 0.04 for two SNPs at
baseline, respectively, and P  0.02 for both SNPs at the
follow-up examination) with an allele-dose effect. Carriers
of the minor alleles of the two SNPs had, on average,
0.2–0.3 kg/m
2 decreased BMI per allele copy. The third
SNP (rs497849) that tags haplotype 2 showed no associa-
tion with BMI. Haplotype analysis offered little additional
information. For haplotype 1, which contains the major
alleles for two SNPs associated with BMI (rs7895833 and
rs1467568), we observed a signiﬁcant positive association
with BMI that was stronger at the second follow-up (	
0.273, P  0.008) than at baseline (	0.130, P  0.07).
Haplotype 4 showed no association with BMI (data not
shown).
Similar to the ﬁndings in the Rotterdam Study, carriers
of the minor alleles of rs7895833 and rs1467568 had a
lower BMI in the ERF study (P  0.03 and 0.008 for the
two SNPs, respectively). To exclude that associations
between the SNPs and BMI were explained by a difference
in body height, we also analyzed the relation between the
SNPs and height. No differences in height were seen
between the genotypes (data not shown).
Combined analysis of relation of SIRT1 variants with
BMI in two studies. The combined analysis (Table 2) on
the outcomes of the two studies, the Rotterdam Study
baseline and the ERF study, showed a highly signiﬁcant
association with BMI (P  0.002 for both SNPs).
Relation of SIRT1 variants with BMI change during
follow-up in the Rotterdam Study. Table 2 also pre-
sents data from linear regression analysis of change in BMI
or body weight from baseline to second follow-up for three
SNPs in the SIRT1 gene in the Rotterdam Study over a
period of 6.4 years on average. The two SNPs, rs7895833
and rs1467568, that were associated with BMI at baseline
and follow-up and with the risk of overweight and obesity
were also associated with BMI change at the second
follow-up examination. After adjustment for age and sex,
the P value for trend was 0.01 for rs7895833 and P  0.08
for rs1467568. Adjustment for BMI at baseline did not
change these results, and ﬁndings were similar when
change of body weight instead of BMI was assessed (data
not shown).
SIRT1 variants and risk of overweight/obesity. Table
3A presents the odds ORs and 95% CIs for the risk of being
overweight (BMI 25 kg/m
2) compared with being normal
weight (BMI 18.5–25 kg/m
2) for the two SNPs in the SIRT1
gene in the Rotterdam Study at baseline and in the
replication cohort of the ERF study. In the Rotterdam
Study, carriers of the minor alleles of rs7895833 had 12%
decreased OR (95% CI) of being overweight compared
with noncarriers (0.88 [0.79–0.99], P  0.03). For
rs1467568, a similar, yet not signiﬁcant, trend was seen
with an OR of 0.91 (0.82–1.02). Similar results were
observed in the ERF study, with the strongest and most
signiﬁcant effect for rs1467568. At the second follow-up
measurement of the Rotterdam Study (n  3,630), the risk
of overweight in relation to SIRT1 was similar to the risk
at baseline but did not reach statistical signiﬁcance (for
rs7895833: 0.91 [0.79–1.05], P  0.21; for rs1467568: 0.90
[0.78–1.04], P  0.14, data not shown).
In Table 3B, the ORs and 95% CIs for the risk of being
obese (BMI 30 kg/m
2) compared with being normal
weight (BMI 18.5–25 kg/m
2) are presented for two SNPs in
the SIRT1 gene in the two studies. In the Rotterdam Study,
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Carriers of minor alleles of the two SNPs had a 20–21%
decreased risk (for rs7895833: 0.79 [0.67–0.94], P  0.007;
for rs1467568: 0.80 [0.68–0.94], P  0.007). Similar trends
were seen in the ERF study population, only statistically
signiﬁcant for rs1467568. At the second follow-up mea-
surement of the Rotterdam Study, the association with
risk of obesity was similar for carriers of the two SNPs (for
rs7895833: 0.78 [0.64–095], P  0.01; for rs1467568: 0.69
[0.57–0.84], P  0.0002, data not shown).
Combined analysis of the risk of overweight/obesity
in two studies. Table 3 also presents the data from the
meta-analysis of the risk of overweight or obesity for the
two SNPs in the SIRT1 gene in the Rotterdam Study at
baseline and the ERF study. Carriers of the minor alleles of
two SNPs had 9–11% decreased risk of being overweight
compared with noncarriers (for rs7895833: OR 0.91 [95%
CI 0.84–0.99], P  0.02; for rs1467568: 0.89 [0.83–0.97],
P  0.005), with evidence for allele dose effects (P value
additive model  0.006 and 3.5 
 10
6 for rs7895833 and
rs1467568, respectively). The risk for obesity was de-
creased by 13–18% (for rs7895833: 0.87 [0.77–0.97], P 
0.02; for rs1467568: 0.82 [0.73–0.92], P  0.0009), with
allele dose effects (P value additive models 0.009 and 0.002
for rs7895833 and rs1467568, respectively). The P values
for the recessive model were always higher than those for
the dominant or additive models.
Meta analysis with published data. Figure 2 shows a
forest plot from the meta-analysis of risk of obesity for
carriers compared with noncarriers of the A allele of
rs1467568 in the Rotterdam and ERF studies and the C
allele of rs7069102 from the study by Peeters et al. (30).
The A and C alleles of these SNPs are in high LD (r
2 
0.96). The combined OR for the three studies was 0.81
(95% CI 0.73–0.90) (P  0.00007).
DISCUSSION
In this study, we show in two large and independent Dutch
Caucasian populations that the minor alleles of two com-
mon SIRT1 variants are associated with a decreased BMI.
Carriers of these two common genetic variants had 9–11%
decreased risk of being overweight and 13–18% decreased
risk of being obese compared with noncarriers. In line
with these ﬁndings, we also observed in the Rotterdam
Study that carriers of these SIRT1 variants had a smaller
increase of BMI over a 6.4-year follow-up period.
Our study is hypothesis driven and based on the known
functions of SIRT1 in cell cultures and animal studies,
such as an inhibitory effect of SIRT1 on PPAR- in adipose
tissue (14) and a stimulatory effect on PPAR coactiva-
tor-1 (PGC-1) (24,25). This powerful transcriptional
coactivator is regarded as a key mediator of many of the
known beneﬁcial effects of physical activity on skeletal
muscle physiology (40). Treatment of mice with resvera-
trol leads to increased mitochondrial biogenesis and in-
creased energy expenditure in mice, possibly by SIRT1-
mediated increase in PGC-1 activity (25). It is also
possible that the effects on BMI are caused by an inﬂuence
of SIRT1 on appetite and energy intake, since SIRT1 is
highly expressed in brain (41).
Interestingly, SIRT1 has recently been shown to modu-
late CLOCK-gene expression (42–44), and it may thus form
an intriguing link between sensing of cellular metabolism
and the circadian clock, which merits further study.
Inhibitory effects of SIRT1 on differentiation of skeletal
myoblasts have been shown under glucose-restricted con-
ditions in relation to activation of the AMP-activated
protein kinase (45). Therefore, we cannot exclude that
effects on lean mass as well as on fat mass explain the
relation with BMI that we observed. Further studies are
needed to investigate the relation between SIRT1 genetic
variants and human body composition traits and muscle
strength. Yet, the strong association with the risk of
obesity that we found makes a predominant effect on lean
mass unlikely since obesity is associated more strongly
with excess adipose tissue than with excess muscle mass.
This is the ﬁrst large, population-based study reporting
an association between SIRT1 genetic variation and BMI
and obesity in humans with validation in an independent,
population-based cohort. Two recently published genetic
studies in humans corroborate our ﬁndings. In a Belgian
case-control study with 1,068 obese patients and 313
normal-weight control subjects, carriers of the minor
allele of the SNP rs7069102 (which is in high LD [r
2  0.96]
with our SNP rs1467568) had a reduced obesity risk (OR
0.74 [95% CI 0.57–0.96], P  0.025) (30). After including
their results in a meta-analysis with our results, the
association became more signiﬁcant and the combined P
value decreased from 9 
 10
4 to 7 
 10
5. In their study,
the variant that was protective against obesity was asso-
ciated with increased visceral obesity as measured by
computed tomography scanning after adjusting for BMI in
obese male, but not female, subjects. This unexpected
ﬁnding may be caused by overadjustment when the de-
crease in BMI is caused by a decrease in lean as well as in
fat mass or represent a real sex-speciﬁc effect, which
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper
ratio limit limit
p-value
Rotterdam study 0.80 0.68 0.94 0.007
ERF study 0.85 0.73 0.99 0.04
Peeters et al. 0.74 0.57 0.96 0.02
0.81 0.73 0.90 0.00007
0.5 1 2
Meta-analysis
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper
ratio limit limit
p-value
Rotterdam study 0.80 0.68 0.94 0.007
ERF study 0.85 0.73 0.99 0.04
Peeters et al. 0.74 0.57 0.96 0.02
0.81 0.73 0.90 0.00007
5 1 2
Meta-analysis
FIG. 2. Meta-analysis on the risk of obesity from three studies by SIRT1 genotype for carriers compared with noncarriers of the A allele of
rs1467568 in the Rotterdam Study and ERF study and the C allele of rs7069102 from the study by Peeters et al. (30).
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overweight German Caucasian subjects found no signiﬁ-
cant change in BMI by SIRT1 genotype, yet we discovered
in their data a similar decrease in BMI as we found for two
SNPs in high LD with ours (31). For carriers of the minor
variants of rs7069102 (r
2  0.96 with rs1467568), BMI was
2.4% lower, and for rs730821 (r
2  1.0 with rs7895833),
BMI was 6.1% lower, compared with noncarriers. These
differences were not signiﬁcant, possibly because of low
power. Recent GWA studies have shown that common
SNPs contributing to common complex diseases have
modest effects and require large sample sizes to be discov-
ered (46). The absence of SIRT1 among the genome-wide
signiﬁcant new ﬁndings in recent GWA studies for BMI
may be explained by the stringent criteria used to correct
for multiple testing in GWA studies and shows the added
value of candidate gene analyses.
The strength of our study is the use of two large and
independent population-based cohorts with consistency of
ﬁndings between studies and between cross-sectional and
longitudinal analyses. The ﬁndings robustly show that
SIRT1 variants inﬂuence human obesity. A limitation of
our study is the use of tagging SNPs. The SNPs we selected
are noncoding and we therefore assume these two variants
to be linked with one or more functional variants within
the SIRT1 gene or its regulatory regions. This will require
more in-depth molecular studies. Future ﬁne mapping and
resequencing of the SIRT1 gene may detect such func-
tional variants. Further studies into underlying mecha-
nisms and body composition are also needed as well as
prospective studies on a relation with obesity-associated
diseases. Because we have no information on functionality
of the genetic variants, we cannot conclude from our data
whether the lower BMI that we observed in carriers of
the minor alleles of the two SIRT1 SNPs is associated
with increased or decreased SIRT1 activity. However,
based on the known functions of SIRT1, one could
speculate that the minor alleles of rs7895833 and
rs1467568 are linked with functional variants leading to
increased SIRT1 activity.
The results of our study may have important clinical
implications. Obesity has become a global epidemic and
represents an important risk factor for type 2 diabetes,
hypertension, cardiovascular disease, stroke, some types
of cancer, and disability. Few, if any, effective options for
treatment and prevention are available. The ﬁndings of our
study are in line with speculations that modulators of
SIRT1 activity may decrease BMI and the risk of becoming
overweight and obese and may thus provide a valuable
new strategy for treatment and prevention of obesity and
its related diseases. An attractive aspect of our ﬁndings is
that, in contrast to novel genetic ﬁndings from GWA
studies, many data exist on SIRT1 biological functions,
while in addition several SIRT1 modiﬁers have already
been identiﬁed. The protective effects of the SIRT1-stimu-
lating ﬂavenoid resveratrol against diet-induced obesity in
mice may potentially apply to humans as well (25), but its
effects are not only SIRT1 mediated (47,48) and low
bioavailability is a concern (49). More research on phar-
macology and possible side effects in humans is necessary
for this compound as well as for recently developed more
potent SIRT1 activators (50). Alternatively, SIRT1 inhibi-
tors might be of use in cachexia.
In summary, we found that carriers of two common
variants in the SIRT1 gene have lower BMI, a 13–18%
decreased risk of being obese, and less BMI gain in time.
Together with results from recent studies, these consistent
ﬁndings warrant research into a potential role for SIRT1
modulators in prevention and treatment of human obesity.
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